Nanophase Reports Record Second Quarter Revenue

In this article:
Nanophase Technologies CorporationNanophase Technologies Corporation
Nanophase Technologies Corporation

— Delivered $11.9 Million in Q2 revenue  
— Product revenue up 10% in Q2 and 12% YOY 
— Profitable Quarter 
— Won Cosmopack Formulation Award at Cosmoprof North America 

ROMEOVILLE, Ill., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced financial results for the second quarter ended June 30, 2023.

Jess Jankowski, President and Chief Executive Officer, commented: “It’s been a strong second quarter.  We built on last quarter’s volume while enhancing margins nicely, as expected.  Our gross profit for Q2 was 31%, both stronger than Q1’s, and much stronger than last year’s second quarter. We are expecting further margin improvement in Q3 as we continue to gain operational efficiencies in our new facility, aided by new senior manufacturing leadership.  Given current order visibility, we expect to deliver quarterly profits in Q3, and a modest full-year profit.”

  • 7% Net income before litigation costs for Q2

  • 1% Net income before litigation costs 2023 year to date

Kevin Cureton, Chief Operating Officer, commented: “During Q2 we continued to see positive results from the improvements to labor efficiency and overall throughput we began implementing in Q1. We successfully combined these improvements in operating performance with continued revenue growth resulting from a combination of unit volume and price improvements, and of course, we continued our world-class performance as a leading innovator in the Skin Health and Beauty business.” 
 
Operational Highlights

Solésence Beauty Science Wins Major Beauty Industry Award for Second Time

  • In July, Solésence won Best Formulation at Cosmopack North America for the second year in a row. The 2023 award recognized the Solésence market-ready product, Natural Glow Face Oil, SPF 40+ Featuring Kleair™ and Bloom™.  

Operational Highlights (continued)

The Cosmoprof North America Awards and Cosmopack North America Awards are “[t]he American Beauty Competition that celebrates the greatest innovation in the beauty industry,” according to the Awards website. The Cosmopack North America Awards set in particular “formally recognizes the best in beauty formulation and packaging design.”  As an added benefit this year, the winner of each category will also have their products showcased at Cosmoprof Worldwide Bologna 2024 as part of a larger showcase of the Cosmoprof Network's winners.

Production Milestone: Establishing Platform for Operational Excellence

  • New VP manufacturing, Harrison King, joined the team in June. Harrison brings over 20 years of manufacturing and supply chain leadership, including management roles with Avon, Blistex, and Amazon, as well as diverse experience in quality from the textile industry.   

  • First fully automated filling process completed validation resulting in 200% increase in capacity without any additional labor costs.   

Financial Highlights

  • Revenue for Q2 was $11.9 million, vs. $11.2 million for the same period in 2022, yielding a 10% increase in product revenue and a 6% increase overall.  

  • Revenue for the six months ended June 30, 2023 was $21.3 million, vs. $19.4 million for the same period in 2022, yielding a 12% increase in product revenue and a 10% increase overall.  

“We had $15 million in open P.O.s and shipped orders combined leaving June, more than two-thirds of which reflect potential Q3 volume. We expect more orders for Q4 shipments, followed by more 2024 order volume later this year. We’re excited about our prospects for Q3, particularly in terms of margin improvement,” said Jankowski.

Conference Call

Nanophase will host its Second Quarter Conference Call on Thursday, August 3rd, 2023, at 10:00 a.m. CDT, 11:00 a.m. EDT, to discuss its financial results and provide a business and financial update. On the call will be Jess Jankowski, the Company’s President & CEO, joined by Kevin Cureton, the Company’s Chief Operating Officer.

Participant Registration:
https://register.vevent.com/register/BIb465a5fa073e46aca402f402c74a7f77

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call has begun. If you forget your PIN prior to the conference call, you can simply re-register.

The process for accessing the webcast as listen-only remains the same. The same link can be used after the call to access the replay. A Telco replay is no longer available.

Listen-Only Webcast & Replay:
https://edge.media-server.com/mmc/p/g9w7bzft

Please connect to the conference at least five minutes before the call is scheduled to begin.

The call may also be accessed through the company’s website, at http://www.nanophase.com/, by clicking on Investor Relations, Investor News, and the links in this conference call announcement release.

FINANCIAL RESULTS AND NON-GAAP INFORMATION 
Use of Non-GAAP Financial Information 
Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Nanophase Technologies 
Nanophase Technologies Corporation (OTCQB: NANX), www.nanophase.com, is a leading innovator in minerals-based and scientifically driven healthcare solutions across beauty and life science categories, as well as other legacy advanced materials applications. Leveraging a platform of integrated, patented and proprietary technologies, the Company creates products with unique performance, enhancing consumers' health and well-being. We deliver commercial quantity and quality engineered materials both as ingredients and as part of fully formulated products in a variety of formats.

About Solésence Beauty Science 
Solésence, www.solesence.com, a wholly owned subsidiary of Nanophase Technologies, is changing the face of skin health with patented, mineral-based technology that is embraced by leading performance-driven and clean beauty brands alike. Our patented products for brands transform the way mineral actives look, feel and function — enabling textures never-before-seen in the mineral space and inclusivity never-before-seen in the sun care space. Solésence’s innovative formulations offer best-in-class UV protection, unparalleled free radical prevention to protect against pollution, and enhanced antioxidant performance.

Forward-Looking Statements 
This press release contains words such as “expects,” shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 29, 2023. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies. 




NANOPHASE TECHNOLOGIES CORPORATION

 

 

 

 

 

 

 

 

CONSOLIDATED BALANCE SHEETS

 

(Unaudited Consolidated Condensed)

 

 

 

 

(in thousands except share and per share data)

 

 

 

 

 

 

 

 

June

 

December 31,

 

 

 

 

 

2023

 

 

 

2022

 

 

ASSETS

(Unaudited)

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash

$

2,197

 

 

$

2,186

 

 

 

Trade accounts receivable, less allowance for doubtful accounts of $324

 

 

 

 

 

 

for June 30, 2023 and $139 for December 31, 2022

 

5,718

 

 

 

4,734

 

 

 

Inventories, net

 

8,412

 

 

 

8,839

 

 

 

Prepaid expenses and other current assets

 

1,043

 

 

 

866

 

 

 

 

Total current assets

 

17,370

 

 

 

16,625

 

 

 

 

 

 

 

 

 

 

Equipment and leasehold improvements, net

 

8,459

 

 

 

7,949

 

 

 

Operating leases, right of use

 

8,468

 

 

 

8,978

 

 

 

Other assets, net

 

5

 

 

 

6

 

 

 

 

 

$

34,302

 

 

$

33,558

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

 

Lines of credit, related party

 

8,592

 

 

 

7,282

 

 

 

Current portion of finance lease obligations

 

 

 

 

 

Current portion of operating lease obligations

 

 

 

 

 

Accounts payable

 

4,957

 

 

 

6,363

 

 

 

Current portion of long-term debt, related parites

 

2,338

 

 

 

-

 

 

 

Current portion of deferred revenue

 

2,053

 

 

 

2,167

 

 

 

Accrued expenses

 

1,442

 

 

 

1,023

 

 

 

 

Total current liabilities

 

19,382

 

 

 

16,835

 

 

 

 

 

 

 

 

 

 

Long-term portion of finance lease obligations

 

 

 

 

 

Long-term portion of operating lease obligations

 

9,482

 

 

 

9,823

 

 

 

Long-term debt, related party

 

-

 

 

 

1,000

 

 

 

Long-term portion of deferred revenue

 

45

 

 

 

21

 

 

 

Asset retirement obligation

 

234

 

 

 

230

 

 

 

 

Total long-term liabilities

 

9,761

 

 

 

11,074

 

 

 

 

 

 

 

 

 

Contingent liabilities

 

-

 

 

 

-

 

 

Stockholders' equity:

 

 

 

 

 

Preferred stock, $.01 par value, 24,088 shares authorized and

 

 

 

 

 

 

no shares issued and outstanding

 

-

 

 

 

-

 

 

 

Common stock, $.01 par value, 60,000,000 and 55,000,000 shares authorized;

 

 

 

 

 

 

49,589,204 and 49,320,680 shares issued and outstanding on June 30, 2023

 

 

 

 

 

 

and December 31, 2022, respectively

 

495

 

 

 

493

 

 

 

Additional paid-in capital

 

105,763

 

 

 

105,226

 

 

 

Accumulated deficit

 

(101,099

)

 

 

(100,070

)

 

 

 

Total stockholders' equity

 

5,159

 

 

 

5,649

 

 

Total liabilities and shareholders' equity

$

34,302

 

 

$

33,558

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



NANOPHASE TECHNOLOGIES CORPORATION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

(Unaudited Consolidated Condensed)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

 

 

 

 

 

 

June 30,

 

June 30,

 

 

 

 

 

 

 

 

2023

 

 

2022

 

 

2023

 

 

 

2022

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

11,844

 

$

10,796

 

$

21,180

 

 

$

18,842

 

 

 

Other revenue

 

 

28

 

 

426

 

 

149

 

 

 

536

 

 

 

 

Net revenue

 

 

11,872

 

 

11,222

 

 

21,329

 

 

 

19,378

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

8,197

 

 

8,486

 

 

15,505

 

 

 

14,474

 

 

 

 

Gross profit

 

 

3,675

 

 

2,736

 

 

5,824

 

 

 

4,904

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expense:

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

991

 

 

797

 

 

1,994

 

 

 

1,463

 

 

 

Selling, general and administrative expense

 

 

2,105

 

 

1,816

 

 

4,255

 

 

 

3,213

 

 

Income from operations

 

 

579

 

 

123

 

 

(425

)

 

 

228

 

 

 

Interest expense

 

 

246

 

 

73

 

 

400

 

 

 

116

 

 

 

Other income, net

 

 

-

 

 

-

 

 

-

 

 

 

-

 

 

Income before provision for income taxes

 

 

333

 

 

50

 

 

(825

)

 

 

112

 

 

Provision for income taxes

 

 

-

 

 

-

 

 

-

 

 

 

-

 

 

Net income (loss)

 

$

333

 

$

50

 

$

(825

)

 

$

112

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share-basic

 

$

0.01

 

$

-

 

$

(0.02

)

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding - basic

 

 

49,562,624

 

 

49,045,047

 

 

49,498,755

 

 

 

49,014,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share-diluted

 

$

0.01

 

$

-

 

$

-

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding - diluted

 

50,679,013

 

 

51,008,047

 

 

-

 

 

 

50,990,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE

 

 

(Unaudited Consolidated Condensed)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

 

 

 

 

 

 

June 30,

 

June 30,

 

 

 

 

 

 

 

 

2023

 

 

2022

 

 

2023

 

 

 

2022

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

11,844

 

$

10,796

 

$

21,180

 

 

$

18,842

 

 

 

Other revenue

 

 

28

 

 

426

 

 

149

 

 

 

536

 

 

 

 

Net revenue

 

 

11,872

 

 

11,222

 

 

21,329

 

 

 

19,378

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expense:

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue detail:

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

158

 

 

120

 

 

316

 

 

 

239

 

 

 

Non-Cash equity compensation

 

 

28

 

 

24

 

 

55

 

 

 

49

 

 

 

Other costs of revenue

 

 

8,011

 

 

8,342

 

 

15,134

 

 

 

14,186

 

 

 

 

Cost of revenue

 

 

8,197

 

 

8,486

 

 

15,505

 

 

 

14,474

 

 

 

 

 

Gross profit

 

 

3,675

 

 

2,736

 

 

5,824

 

 

 

4,904

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense detail:

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

7

 

 

9

 

 

14

 

 

 

18

 

 

 

Non-Cash equity compensation

 

 

45

 

 

41

 

 

92

 

 

 

82

 

 

 

Other research and development expense

 

 

939

 

 

747

 

 

1,888

 

 

 

1,363

 

 

 

 

Research and development expense

 

 

991

 

 

797

 

 

1,994

 

 

 

1,463

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expense detail:

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

8

 

 

5

 

 

15

 

 

 

12

 

 

 

Non-Cash equity compensation

 

 

123

 

 

90

 

 

258

 

 

 

171

 

 

 

Other selling, general and administrative expense

 

 

1,974

 

 

1,721

 

 

3,982

 

 

 

3,030

 

 

 

 

Selling, general and administrative expense

 

 

2,105

 

 

1,816

 

 

4,255

 

 

 

3,213

 

 

Income from operations

 

 

579

 

 

123

 

 

(425

)

 

 

228

 

 

 

Interest expense

 

 

246

 

 

73

 

 

400

 

 

 

116

 

 

 

Other income, net

 

 

-

 

 

-

 

 

-

 

 

 

-

 

 

Income before provision for income taxes

 

 

333

 

 

50

 

 

(825

)

 

 

112

 

 

Provision for income taxes

 

 

-

 

 

-

 

 

-

 

 

 

-

 

 

Net (loss) income

 

$

333

 

$

50

 

$

(825

)

 

$

112

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):

 

 

 

 

 

 

 

 

 

 

Addback Interest, net

 

 

246

 

 

73

 

 

116

 

 

 

116

 

 

 

Addback Depreciation/Amortization

 

 

134

 

 

134

 

 

269

 

 

 

269

 

 

 

Addback Non-Cash Equity Compensation

 

 

135

 

 

155

 

 

302

 

 

 

302

 

 

 

Subtract Non-Cash Other Income

 

 

-

 

 

-

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

848

 

$

412

 

$

(138

)

 

$

799

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 





Investor Relations Contact: 
Phone: (630) 771-6736



Advertisement